Acorda writes off $363M drug, axing PhIII Parkinson’s drug in the wake of 5 patient deaths
Five days after Acorda said it was suspending enrollment after tracking the deaths of 5 patients from sepsis in a late-stage study of the Parkinson’s drug tozadenant, the deeply troubled biotech says it’s decided to scrap the drug altogether as too dangerous to keep in the clinic.
According to Acorda, researchers tracked new information about its number two drug in the pipeline that convinced the company to discontinue the work on a drug that cost them $363 million in an all-cash buyout.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.